Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1081 to 1095 of 1259 results for pathway

  1. Head injury (QS74)

    This quality standard covers assessment, early management and rehabilitation following head injury in adults, young people and children. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    15 October 2025
    View quality statements

    Sections for QS74

  2. Adults' uptake of and engagement with interventions for social anxiety disorder:- What methods are effective in improving uptake of and engagement with interventions for adults with social anxiety disorder?

    uptake and engagement, including: - Development and evaluation of improved pathways into care, in collaboration with low users of...

    Research recommendation
    Published
    9 June 2015

  3. Techniques for confirming a diagnosis in people with suspected atypical Spitzoid melanocytic lesions: In people with reported atypical Spitzoid lesions, how effective are fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH) and tests to detect driver mutations compared with histopathological examination alone in predicting disease specific survival? This should be investigated ina prospective diagnostic study. Secondary outcomes should include sensitivity, specificity, accuracy, positive predictive value, disease specific survival and progression free survival.

    and may not be conclusive. Understanding and mapping changes in molecular pathways could predict outcome and inform individual treatment...

    Research recommendation
    Published
    4 August 2022

  4. Routine outcome measurement:- In people with a common mental health disorder, what is the clinical utility of routine outcome measurement and is it cost effective compared with standard care?

    Comes from guidance Common mental health problems: identification and pathways to care Number CG123 Date issued May 2011 Other

    Research recommendation
    Published
    9 June 2015

  5. Fremanezumab for preventing migraine (TA764)

    Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.

    Technology appraisal guidance
    Published
    2 February 2022
    View recommendations

    Sections for TA764

  6. Generalized Anxiety Disorder scale (GAD-2) for people with suspected anxiety disorders:- In people with suspected anxiety disorders, what is the clinical utility of using the GAD-2 compared with routine case identification to accurately identify different anxiety disorders? Should an avoidance question be added to improve case identification?

    Comes from guidance Common mental health problems: identification and pathways to care Number CG123 Date issued May 2011 Other

    Research recommendation
    Published
    9 June 2015

  7. Identifying health conditions:- What is the effectiveness and cost effectiveness of different ways of identifying age-related and other physical and mental health conditions, in people growing older with learning disabilities?What can mainstream and specialist health services do to facilitate:- early identification of health conditions in people with learning disabilities?- equal access to health services in people with learning disabilities?

    health checks, we did not find any evidence about different methods and pathways for identifying health conditions among people growing...

    Research recommendation
    Published
    29 November 2018

  8. Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)

    Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making

    Evidence summary
    Published
    13 March 2013

  9. Interim methods guide for developing service guidance 2014 (PMG8)

    This manual provides information additional to that in Developing NICE guidelines: the manual to guide developers on how to approach developing service guidance, and also to inform stakeholders about the steps that NICE will take in developing this guidance

  10. Use of a simple algorithm compared with a standard clinical assessment:- For people with a common mental health disorder, is the use of a simple algorithm (based on factors associated with treatment response), when compared with a standard clinical assessment, more clinically and cost effective?

    Comes from guidance Common mental health problems: identification and pathways to care Number CG123 Date issued May 2011 Other

    Research recommendation
    Published
    9 June 2015

  11. Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor (TA1103)

    Evidence-based recommendations on lorlatinib (Lorviqua) for treating ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor in adults.

    Technology appraisal guidance
    Published
    21 October 2025

    Sections for TA1103

  12. Burosumab for treating X-linked hypophosphataemia in adults (TA993)

    Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.

    Technology appraisal guidance
    Published
    7 August 2024
    View recommendations

    Sections for TA993

  13. Intrapartum care (QS105)

    This quality standard covers the care of women and their babies during labour and immediately after the birth. It covers women who go into labour at term, and includes women at low risk of complications during labour and those who go on to develop complications. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    28 February 2017
    View quality statements

    Sections for QS105

  14. Spiral Flow peripheral vascular graft for treating peripheral arterial disease (MIB34)

    NICE has developed a medtech innovation briefing (MIB) on the Spiral Flow peripheral vascular graft for treating peripheral arterial disease

    Medtech innovation briefing
    Published
    21 July 2015

  15. Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over (TA1003)

    Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for transfusion-dependent beta-thalassaemia in people 12 years and over.

    Technology appraisal guidance
    Published
    11 September 2024
    View recommendations

    Sections for TA1003